Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock Rating Upgraded by StockNews.com
Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) was upgraded by research analysts at StockNews.com from a “sell” rating to a “hold” rating in a research note issued to investors on Monday. Several other research firms have also recently commented on MDGL. Citigroup raised their target price on shares of Madrigal Pharmaceuticals from $378.00 to $469.00 […]
Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) was upgraded by research analysts at StockNews.com from a “sell” rating to a “hold” rating in a research note issued to investors on Monday. Several other research firms have also recently commented on MDGL. Citigroup raised their target price on shares of Madrigal Pharmaceuticals from $378.00 to $469.00 […]
